Last updated: September 2, 2026
Desloratadine/pseudoephedrine sulfate is a mature prescription combination marketed in the United States as Clarinex-D. The product combines desloratadine, a long-acting antihistamine, with extended-release pseudoephedrine, a nasal decongestant. Its commercial position has weakened because core desloratadine patent protection expired years ago, generic competition is established, and pseudoephedrine purchasing restrictions limit distribution. The product remains commercially relevant in seasonal allergic rhinitis, but its financial profile is primarily a low-growth generic and private-label market rather than an innovative branded-drug opportunity.
What is desloratadine/pseudoephedrine sulfate and how is it marketed?
Desloratadine/pseudoephedrine sulfate is an oral extended-release combination for allergic rhinitis with nasal congestion. The branded product was developed by Schering-Plough and later commercialized within Merck’s respiratory and allergy portfolio.
| Product |
Active ingredients |
Dosage form |
U.S. regulatory status |
Principal use |
| Clarinex-D 12 Hour |
Desloratadine 2.5 mg plus pseudoephedrine sulfate 120 mg |
Extended-release tablet |
Prescription NDA |
Allergic rhinitis with congestion |
| Clarinex-D 24 Hour |
Desloratadine 5 mg plus pseudoephedrine sulfate 240 mg |
Extended-release tablet |
Prescription NDA |
Allergic rhinitis with congestion |
| Generic equivalents |
Desloratadine plus pseudoephedrine sulfate |
Extended-release tablets |
ANDA pathway |
Therapeutic substitution |
The combination is distinct from loratadine/pseudoephedrine products such as Claritin-D. Desloratadine is the active metabolite of loratadine and is marketed separately as Clarinex. The pseudoephedrine component provides decongestant activity but creates regulatory and supply-chain burdens that do not apply to desloratadine-only products.
What patents protect desloratadine and the combination product?
The key composition-of-matter protection for desloratadine is expired. The principal historical U.S. patent family covering desloratadine and related antihistaminic compounds was assigned to Schering Corporation and included U.S. Patent No. 5,595,997. Its effective U.S. patent term ended in the mid-2010s, subject to patent-term adjustment and regulatory exclusivity calculations recorded for the relevant product.
| Protection category |
Historical position |
Current commercial effect |
| Desloratadine active-ingredient protection |
Expired |
Does not block generic desloratadine |
| Pseudoephedrine sulfate |
Long-established active ingredient |
No meaningful exclusivity barrier |
| Clarinex-D formulation protection |
Historical product-specific patents and regulatory exclusivity |
No material current barrier to ANDA competition |
| Method-of-use protection |
Allergy and nasal-congestion indications |
Broad clinical claims have limited post-expiration value |
| Trade secrets and manufacturing know-how |
Potentially retained by manufacturers |
May affect cost and quality but does not prevent substitution |
The commercial value of the estate now lies mainly in manufacturing capability, formulation consistency, product availability, and channel access. Patent exclusivity does not provide a durable premium.
What formulations are protected by Clarinex-D patents?
Clarinex-D uses an extended-release tablet architecture that separates immediate antihistamine delivery from sustained pseudoephedrine release. Formulation patents historically could cover release profiles, tablet compositions, coatings, excipients, or manufacturing processes. Those claims may have delayed or complicated generic development, but they do not create a current branded monopoly where the relevant claims have expired or become commercially immaterial.
Generic manufacturers still must demonstrate pharmaceutical equivalence and bioequivalence. Extended-release products can face more complex development requirements than immediate-release tablets because release kinetics must match the reference listed drug. This creates a technical hurdle, but it is a development hurdle rather than a durable patent barrier.
When does desloratadine/pseudoephedrine lose exclusivity?
The product lost meaningful market exclusivity in stages:
| Milestone |
Approximate timing |
Commercial consequence |
| Desloratadine launched as Clarinex |
2001 |
Originator pricing and prescription adoption |
| Clarinex-D introduced |
Mid-2000s |
Combination competition with Claritin-D |
| Core desloratadine patent protection ended |
Mid-2010s |
Generic desloratadine entry became legally possible |
| Pediatric and regulatory exclusivities ended |
Mid-2010s or earlier, depending on presentation |
No durable FDA exclusivity remained |
| Generic combination competition |
Post-expiration period |
Price erosion and reduced brand leverage |
| Current market |
2020s |
Mature generic, seasonal, fragmented market |
The precise date for a particular patent claim depends on the patent, patent-term adjustment, pediatric extension, and the approved product associated with the listing. The practical conclusion is consistent: current U.S. sales are not protected by active composition-of-matter exclusivity.
What is the FDA and Orange Book status of Clarinex-D?
Clarinex-D was approved through the FDA new drug application pathway as a prescription extended-release combination. Generic versions are eligible for approval through abbreviated new drug applications if they establish pharmaceutical equivalence and bioequivalence to the listed reference product.
FDA regulatory considerations include:
- The reference product must be identified in the Orange Book for the relevant dosage form and strength.
- Generic applicants must match the active ingredients, strength, dosage form, route, and release characteristics.
- Pseudoephedrine controls affect distribution even after FDA approval.
- The product is not a biologic and has no biosimilar pathway.
- FDA approval does not guarantee unrestricted retail availability because pharmacies must comply with federal and state pseudoephedrine rules.
The Orange Book is the controlling source for current reference-listed-drug status, therapeutic-equivalence codes, and any remaining listed patents or exclusivities. For a mature product such as Clarinex-D, the commercial question is usually whether a generic can be approved and supplied at scale, not whether an unexpired patent blocks entry.
Are there Paragraph IV challenges to desloratadine/pseudoephedrine?
Paragraph IV litigation risk was most relevant when Clarinex-D patents remained enforceable. A generic applicant could certify that a listed patent was invalid, unenforceable, or would not be infringed. That certification could trigger Hatch-Waxman litigation and a potential 30-month stay of ANDA approval.
The current risk profile is different:
| Risk |
Assessment |
| New Paragraph IV challenge to core desloratadine patent |
Low, because core protection is expired |
| Litigation over an old formulation patent |
Low to moderate, depending on any surviving listing |
| ANDA approval delay |
More likely from FDA review, manufacturing, or bioequivalence issues than patent litigation |
| Commercial launch delay |
Possible from pseudoephedrine sourcing and channel restrictions |
| Authorized-generic competition |
Possible and commercially relevant |
A Paragraph IV dispute could still arise around a listed formulation or method patent, but the economic value of such litigation is limited in a market with established generic substitutes and weak brand pricing power.
How strong is the patent estate for desloratadine/pseudoephedrine?
The estate is weak for exclusivity purposes.
Patent-strength assessment
| Factor |
Rating |
Rationale |
| Core active-ingredient protection |
Weak |
Expired |
| Combination-product protection |
Weak to moderate |
Historical formulation claims may have delayed entry but do not provide broad current protection |
| Method-of-use protection |
Weak |
Allergy and congestion uses are established and difficult to enforce commercially |
| Manufacturing protection |
Moderate |
Process knowledge may support quality and cost advantages |
| Regulatory exclusivity |
None of strategic importance |
Product is mature |
| Design-around difficulty |
Moderate |
Extended-release performance requires technical work |
| Litigation leverage |
Low |
Limited remaining exclusivity value |
The main barrier is operational execution. A manufacturer must produce an extended-release tablet that meets dissolution, stability, content-uniformity, and bioequivalence requirements while managing pseudoephedrine controls. Those factors can reduce the number of reliable suppliers, but they do not support the pricing associated with a protected specialty drug.
Which companies compete with desloratadine/pseudoephedrine?
Competition comes from three groups.
Direct combination competitors
The closest direct competitor is loratadine/pseudoephedrine, sold as Claritin-D and generic equivalents. It has similar therapeutic positioning but uses loratadine rather than desloratadine.
Other antihistamine-decongestant combinations include:
- Cetirizine/pseudoephedrine, marketed as Zyrtec-D
- Fexofenadine/pseudoephedrine, marketed as Allegra-D
- Generic antihistamine and pseudoephedrine combinations
Single-agent substitutes
Patients can use desloratadine, loratadine, cetirizine, fexofenadine, or levocetirizine for allergy symptoms and add a separate nasal decongestant or intranasal corticosteroid. Intranasal products such as fluticasone and mometasone compete for congestion and allergic-rhinitis treatment, although they do not provide the same oral combination.
Nonprescription and pharmacy-channel substitutes
Pseudoephedrine products remain available behind the pharmacy counter. Phenylephrine products have historically occupied open-shelf decongestant channels, but FDA scrutiny of oral phenylephrine efficacy has altered the competitive outlook. FDA action and retailer decisions can shift demand toward pseudoephedrine-containing products, but purchase restrictions limit volume expansion.[1]
What is the market and financial trajectory?
Public company filings generally do not disclose standalone revenue for desloratadine/pseudoephedrine sulfate. Sales are commonly aggregated within allergy, respiratory, or consumer-health categories. The product’s financial trajectory can therefore be assessed through market structure rather than a separately reported revenue series.
Financial trajectory
| Period |
Market condition |
Financial effect |
| Launch period |
Branded prescription product with limited direct competition |
High gross margins and premium pricing |
| Patent-expiration period |
Generic desloratadine and competing combinations expand |
Rapid price pressure |
| Mature generic period |
Multiple suppliers and pharmacy substitution |
Lower unit prices, higher volume sensitivity |
| Current period |
Seasonal demand, restricted pseudoephedrine distribution |
Stable but limited growth |
| Long-term outlook |
Commodity-like product with periodic supply disruptions |
Low revenue growth and margin compression |
The brand’s revenue exposure declined after generic entry because antihistamine products are highly substitutable. A branded manufacturer must maintain availability, physician familiarity, or a contracted channel advantage to preserve share. Those advantages are limited for a prescription combination with expired exclusivity.
The generic market can still generate attractive cash flow for efficient manufacturers. Profitability depends on:
- API sourcing for desloratadine and pseudoephedrine sulfate
- Extended-release manufacturing capacity
- FDA compliance history
- Retail pharmacy contracts
- Ability to manage seasonal inventory
- Control of returns and expiry
- Competition among ANDA holders
Pseudoephedrine regulation creates a countervailing effect. It restricts consumer access and raises compliance costs, but it can also reduce the number of effective competitors because not every manufacturer or distributor wants to manage controlled-sale logistics.
What generic launch scenarios exist?
Scenario 1: Broad generic substitution
Multiple approved suppliers compete across both Clarinex-D strengths. This produces the highest price erosion and reduces the originator product to a limited residual share.
Scenario 2: Limited supplier market
Only a small number of manufacturers maintain reliable supply. Prices remain above the lowest generic levels because of manufacturing complexity, seasonal demand, or API constraints.
Scenario 3: Brand or authorized-generic retention
The originator retains a niche through an authorized generic, distributor contracts, or superior supply reliability. This supports volume but rarely restores branded pricing.
Scenario 4: Substitution toward other combinations
Physicians and patients shift to Claritin-D, Zyrtec-D, Allegra-D, or separate intranasal therapy. This is the most likely long-term pressure on desloratadine/pseudoephedrine because the product has limited clinical differentiation.
What manufacturing and intellectual-property barriers remain?
The principal manufacturing barriers are extended-release performance, scale-up consistency, dissolution control, and pseudoephedrine compliance. A generic tablet that contains the correct ingredients but fails release-profile or bioequivalence requirements cannot compete.
Geographic coverage is broad for the active ingredients because both are established small molecules. Manufacturing can occur through U.S., European, Indian, or other regulated supply chains, subject to FDA facility oversight and controlled-substance-adjacent requirements for pseudoephedrine distribution. Supply concentration and API shortages can affect availability more than patent rights.
There is no biosimilar risk because the product is a small-molecule combination. The relevant competitive threats are generic substitution, therapeutic substitution, private-label distribution, and alternative allergy treatments.
What litigation and settlement agreements affect the product?
The most important litigation window was the period surrounding generic entry and the enforceability of listed Clarinex or Clarinex-D patents. Once core patents expired and generic products entered, settlement agreements lost much of their strategic value.
Current litigation exposure is more likely to involve:
- FDA approval disputes
- ANDA patent certifications
- Manufacturing or supply agreements
- Product liability
- Pharmacy and pseudoephedrine compliance
- Antitrust or market-allocation allegations
No settlement should be treated as commercially material without a current court docket, FDA Orange Book record, or SEC disclosure. Historical Hatch-Waxman agreements do not create present exclusivity after the underlying patents expire.
How does Clarinex-D compare with competing allergy combinations?
| Product |
Antihistamine |
Decongestant |
Patent position |
Commercial profile |
| Clarinex-D |
Desloratadine |
Pseudoephedrine |
Expired core protection |
Mature, genericized |
| Claritin-D |
Loratadine |
Pseudoephedrine |
Expired core protection |
Broad consumer recognition |
| Zyrtec-D |
Cetirizine |
Pseudoephedrine |
Expired or mature protection |
Strong allergy franchise |
| Allegra-D |
Fexofenadine |
Pseudoephedrine |
Expired or mature protection |
Established branded and generic demand |
| Desloratadine alone |
Desloratadine |
None |
Generic |
Substitute when congestion is limited |
| Intranasal corticosteroids |
Various |
None |
Mostly generic or OTC |
Strong congestion alternative |
Clarinex-D has no clear patent-based advantage over the competing combinations. Its commercial performance depends on prescribing habits, pharmacy availability, pricing, and patient response.
Key Takeaways
- Desloratadine/pseudoephedrine sulfate is a mature small-molecule combination marketed historically as Clarinex-D.
- Core desloratadine patent protection expired in the mid-2010s, eliminating meaningful composition-of-matter exclusivity.
- Current competitive risk is generic substitution rather than biosimilar competition.
- Extended-release formulation development and pseudoephedrine controls remain operational barriers.
- Standalone product revenue is not generally disclosed by manufacturers, so financial analysis relies on market structure and category-level reporting.
- The long-term outlook is low growth, seasonal demand, price compression, and potential supply-driven margin variation.
- Claritin-D, Zyrtec-D, Allegra-D, single-agent antihistamines, and intranasal corticosteroids limit pricing power.
- Any remaining Paragraph IV or Orange Book issue should be assessed against the current FDA listing because historical patent litigation has limited present economic relevance.
FAQs
Is desloratadine/pseudoephedrine sulfate still patent protected?
No meaningful core patent exclusivity remains in the United States. Any residual formulation or method claims must be evaluated against current FDA Orange Book listings and their expiration dates.
Is Clarinex-D available over the counter?
Clarinex-D was developed as a prescription product. Pseudoephedrine-containing products may be sold without a prescription in some jurisdictions, but they remain subject to behind-the-counter controls, identification requirements, and purchase limits.
Can a generic manufacturer launch desloratadine/pseudoephedrine without a Paragraph IV challenge?
Yes. A generic applicant can use other appropriate ANDA certifications where no blocking unexpired patent remains, or wait until listed patents expire. A Paragraph IV certification is not required in every generic-entry scenario.
Does pseudoephedrine make this product a controlled substance?
Pseudoephedrine is subject to federal and state retail-sale controls because of diversion concerns. Those controls are distinct from the scheduling framework applied to controlled substances such as opioids or stimulants.
Is desloratadine/pseudoephedrine a biosimilar product?
No. Both active ingredients are small molecules. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway under the Public Health Service Act.
References
-
U.S. Food and Drug Administration. (2023). FDA briefing documents: Oral phenylephrine effectiveness. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA, Center for Drug Evaluation and Research.
-
U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Title VII of the USA PATRIOT Improvement and Reauthorization Act.
-
United States Patent and Trademark Office. (n.d.). Patent term calculator and patent term adjustment resources. USPTO.
-
Merck & Co., Inc. (2007). Annual report. Merck & Co., Inc.
